⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Laprophan and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Laprophan
↗Casablanca, Morocco
Founded in 1949, Laprophan is a pioneering Moroccan pharmaceutical company and a leader in the manufacturing, distribution, import, and export of pharmaceutical products. The company provides a wide range of medical drugs covering over 40 specialties and maintains a strong presence in both the private and public sectors in Morocco and across more than 50 countries.
In recent years, Laprophan has pursued an aggressive growth strategy, including the 2023 acquisition of Amanys Pharma and the 2025 acquisition of the Swiss pharmaceutical company Rivopharm. These moves are designed to expand its geographic footprint, enhance its R&D and manufacturing capabilities, and strengthen its position in the generic and specialty drug markets.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Generics and Specialty Pharma
SIZE & FINANCIALS
Employees:501-1000
Founded:1949
Ownership:private
Status:operating
FUNDING
Stage:Private Equity backed
Total Raised:$72.2M
Investors:Mediterrania Capital Partners, DEG, FMO, Proparco
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Amanys Pharma, Rivopharm, Botanic, Europhan
Key Partnerships:International pharmaceutical companies (historical partnerships include Pfizer, P&G, Danone)
COMPETITION
Position:Leader
Competitors:Hikma Pharmaceuticals
LEADERSHIP
Key Executives:
Ali Bennis - President
Scientific Founders:Abderrahim Bennis
LINKS
Website:laprophan.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Laprophan. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.